NLRP3 and diabetes mellitus: Therefore, in the present study, CRAMP may inhibit the activation of colonic MyD88/JNK/NF-κB/NLRP3 signaling pathway, subsequently suppressing the recruitment of IFN-γ+ T cells and their migration to the pancreas in C. rodentium-accelerated diabetes.